Last update 02 Nov 2024

JNJ-41443532

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
JNJ 41443532
Target
CCR2
Mechanism
CCR2 antagonists(C-C chemokine receptor type 2 antagonists)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication-
Inactive Indication
Diabetes Mellitus, Type 2
Originator Organization
Johnson & Johnson Pharmaceutical Research & Development LLC
Active Organization-
Inactive Organization
Johnson & Johnson Pharmaceutical Research & Development LLC
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC22H25F3N4O3S
InChIKeyCFKBNYUHQSQBSX-CYWCHRQTSA-N
CAS Registry1228650-83-6

Related

3
Clinical Trials associated with JNJ-41443532
NCT01230749 / CompletedPhase 2
A Double-Blind, Randomized, Placebo- and Active Comparator-Controlled, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of JNJ-41443532 in Subjects With Type 2 Diabetes Mellitus
NCT01105780 / CompletedPhase 1
Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male and Female Caucasian and Male Japanese Subjects
NCT01106469 / CompletedPhase 1
Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Healthy Male Subjects
100 Clinical Results associated with JNJ-41443532
Login to view more data
100 Translational Medicine associated with JNJ-41443532
Login to view more data
100 Patents (Medical) associated with JNJ-41443532
Login to view more data
100 Deals associated with JNJ-41443532
Login to view more data

External Link

KEGGWikiATCDrug Bank
---
DB12632

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2-
Johnson & Johnson Pharmaceutical Research & Development LLC
01 Dec 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT01230749 (CTgov)
Phase 2
Diabetes Mellitus, Type 2
89
Placebo
rbwzghsyse(wpwgymortm) = gpjkzfnwsk chlijokabs (expntlppfr, hwsqftlrmt - zrtzlxcpmm)
View more
-
11 Dec 2013
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free